We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Human Genome Sciences trial data wow lupus community.
- Authors
Ratner, Mark
- Abstract
The article focuses on an announcement by Rockville, Maryland-based Human Genome Sciences (HGS) that its monoclonal antibody (mAb) drug Benlysta for lupus has met its primary endpoint in the BLISS-52 study, the first of two phase 3 trials. Lupus, an autoimmune disease characterized by the formation of autoantibodies that attack and inflame healthy tissue, affects least 1.5 million people in the U.S. Benlysta targets the B-lymphocyte stimulator (BLyS), a member of the tumor necrosis factor family.
- Subjects
UNITED States; MONOCLONAL antibodies; HUMAN Genome Sciences Inc.; LUPUS erythematosus treatment; CLINICAL trials; TUMOR necrosis factors
- Publication
Nature Biotechnology, 2009, Vol 27, Issue 9, p779
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0909-779